3XUE Q, SANO T, KASHIWABARA K, et al. Aberrant expression of pBb, p16, p14ARF, MDb12, p21 and p53 in stage I adenocarcinomas of the lung[ J ]. Pathol Int, 2002, 52 (2) : 103- 109.
4MENG H, LU C, MABUCHI H,et al. Prognostic significance and different properties of survivin splicing variants in gastric cancer [J]. Cancer Lett, 2004, 216(2) : 147-155.
5MESRI M, WALL NR, LI J, et al. Cancer gene therapy using a survivin mutant adenovirus [ J ]. J Clin Invest, 2001, 108 ( 7 ) : 981-990.
6Xue Q, Sano T, Kashiwabara K, et al. Aberrant expression of pRb, p16, p14ARF, MDM12, p21 and p53 in stage I adenoearcinomas of the lung[J]. Pathol Int,2002,52(2) : 103-109.
7Kawamura K, Yu L, Tomizawa M, et al. Transcriptional regulatory regions of the survivin gene activate an exogenous suicide gene in human tumors and enhance the sensitivity to a prodrug [ J ]. Anticancer Res, 2007, 27(1A) :89 -93.
8Temme A, Rodriguez JA, Hendruschk S, et al. Nuclear localization of Survivin renders HeLa tumor cells more sensitive to apoptosis by induction of p53 and Bax [ J ]. Cancer Lett ,2007,250(2) : 177 - 193.
9Suzuki Y, Oka K, Yoshida D, et al. Correlation between surviving expression and locoregional control in cervical squamous cell carcinomas treated with radiation therapy [ J ]. Gynecol Oncol,2007,104 ( 3 ) : 642 - 646.
10Andrade F, Roy S, Nicholoson D. et al. Granzyme B directly and efficiently cleaves sereral downstreem caspase substrates: imp lication for CTL-induced apoptosis [ J ]. Immunity, 1998,8 (4) :451 - 460.
